Takeda Pharmaceutical Company Limited logo

Takeda Pharmaceutical Company Limited (TKPHF)

Market Closed
11 Dec, 20:00
OTC PINK OTC PINK
$
28. 87
+0.26
+0.91%
$
43.43B Market Cap
- P/E Ratio
2.52% Div Yield
200 Volume
- Eps
$ 28.61
Previous Close
Day Range
28.87 28.87
Year Range
24.25 32.13
Want to track TKPHF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 46 days

Summary

TKPHF closed Thursday higher at $28.87, an increase of 0.91% from Wednesday's close, completing a monthly increase of 9.19% or $2.43. Over the past 12 months, TKPHF stock gained 7.93%.
TKPHF pays dividends to its shareholders, with the most recent payment made on Jun 26, 2025. The next estimated payment will be in 5 months ago on Jun 26, 2025 for a total of $0.6295.
The last earnings report, released on Oct 30, 2025, missed the consensus estimates by -44.31%. On average, the company has fell short of earnings expectations by -14.77%, based on the last three reports. The next scheduled earnings report is due on Jan 29, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

TKPHF Chart

Similar

DCM Holdings Co., Ltd.
$ 8.45
0%
Li Auto Inc.
$ 9.49
0%
San-A Co., Ltd.
$ 15.78
0%
Inditex S.A. Unsponsored ADR
$ 16.38
+1.42%
Industria de Diseño Textil S.A.
$ 65
+3.65%

Takeda Pharmaceutical Company Limited (TKPHF) FAQ

What is the stock price today?

The current price is $28.87.

On which exchange is it traded?

Takeda Pharmaceutical Company Limited is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is TKPHF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2.52%.

What is its market cap?

As of today, the market cap is 43.43B.

What is the earnings per share?

The EPS is 26.2.

When is the next earnings date?

The next earnings report will release on Jan 29, 2026.

Has Takeda Pharmaceutical Company Limited ever had a stock split?

No, there has never been a stock split.

Takeda Pharmaceutical Company Limited Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Christophe Weber CEO
OTC PINK Exchange
JP3463000004 ISIN
JP Country
49,281 Employees
31 Mar 2026 Last Dividend
- Last Split
- IPO Date

Overview

Takeda Pharmaceutical Company Limited is a global leader in the pharmaceutical industry, with core research, development, manufacturing, marketing, and out-licensing activities extending across several key therapeutic areas. Founded in 1781, with its headquarters in Tokyo, Japan, Takeda has evolved into a company with a broad international presence, offering innovative solutions and treatments in gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Takeda's strategic approach includes in-license agreements and collaborations with various biotechnology and pharmaceutical companies, research institutions, and universities worldwide, aiming to deliver transformative treatments and access to innovative therapies for patients globally.

Products and Services

  • Entyvio, Gattex/Revestive, Takecab/Vocinti, and more in Gastroenterology: Takeda offers a range of products targeting gastrointestinal disorders, providing innovative therapies for patients suffering from challenging conditions.
  • Rare Diseases Therapies (Elaprase, Replagal, etc.): The company is committed to addressing the needs of patients with rare and complex diseases, offering specialized treatments and continuing research for new solutions.
  • Plasma Derived Therapies (Adynovate/Adynovi, Feiba, etc.): Takeda excels in providing plasma-derived therapies, essential for treating rare blood disorders and other conditions, solidifying its position as a leader in this specialized field.
  • Immunology (Hyqvia, Cuvitru, etc.): With products designed to modulate the immune system, Takeda supports patients with immunological disorders, facilitating improved health and well-being.
  • Oncology (Ninlaro, Velcade, Adcetris, etc.): Takeda's oncology portfolio addresses various cancer types, offering hope and advanced treatment options to patients battling cancer.
  • Neuroscience (Vyvanse/Elvanse, Trintellix, etc.): Reflecting its dedication to addressing neurological and psychiatric disorders, Takeda provides vital medications for ADHD, depression, and other conditions.

Besides its comprehensive product offerings, Takeda engages in numerous collaborations and licensing agreements. These partnerships span across biotech and pharmaceutical industries, including alliances with BioMarin, Luxna Biotech, GlaxoSmithKline, Neurocrine Biosciences, Seagen, Anima Biotech, and many others, underlining Takeda's commitment to fostering innovation and expanding its therapeutic impact across the globe.

Contact Information

Address: 1-1, Nihonbashi-Honcho 2-chome
Phone: 81 3 3278 2111